This site is intended for healthcare professionals
Drug news

Phase III trial of Kadcyla shows benefits in Breast Cancer

Read time: 1 mins
Last updated:30th Sep 2013
Published:30th Sep 2013
Source: Pharmawand

Results from TH3RESA, a Phase III clinical trial of Kadcyla (ado trastuzumab emtansine), also known as T-DM1, from Genentech/Roche, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive Breast Cancer whose disease has recurred or progressed despite previous treatments. Results showed that median progression-free survival increased by nearly three months from 3.3 months for the conventionally treated patients to 6.2 months for patients receiving Kadcyla. Among the Kadcyla patients, 31.3% showed a response to the drug, compared with 8.6% with conventional treatments.

An interim analysis of overall patient survival showed a similar trend, but it did not reach the level at which a statistically significant benefit for Kadcyla treatment could be confirmed. Generally, there were fewer serious adverse side-effects in the Kadcyla patients than in the control group. Data was presented by Professor Hans Wildiers at the 2013 European Cancer Congress.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.